Nrx Pharmaceuticals Stock Last Dividend Paid

NRXP Stock  USD 2.38  0.10  4.39%   
NRX Pharmaceuticals fundamentals help investors to digest information that contributes to NRX Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NRX Stock. The fundamental analysis module provides a way to measure NRX Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NRX Pharmaceuticals stock.
Other Current LiabTotal Assets
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NRX Pharmaceuticals Company Last Dividend Paid Analysis

NRX Pharmaceuticals' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

 = 

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

NRX Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for NRX Pharmaceuticals is extremely important. It helps to project a fair market value of NRX Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since NRX Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NRX Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NRX Pharmaceuticals' interrelated accounts and indicators.
0.980.00.85-0.910.970.92-0.85-0.480.97-0.95-0.080.74-0.66-0.74-0.74-0.6-0.740.51
0.980.020.81-0.880.950.92-0.93-0.460.95-0.920.050.67-0.6-0.67-0.66-0.55-0.670.44
0.00.020.19-0.050.230.28-0.05-0.790.23-0.24-0.350.29-0.510.230.08-0.630.23-0.29
0.850.810.19-0.920.910.93-0.65-0.720.9-0.9-0.480.97-0.91-0.88-0.9-0.86-0.880.51
-0.91-0.88-0.05-0.92-0.9-0.890.720.54-0.90.880.33-0.870.760.830.850.690.83-0.67
0.970.950.230.91-0.90.97-0.81-0.681.0-0.98-0.230.83-0.8-0.71-0.74-0.77-0.710.45
0.920.920.280.93-0.890.97-0.84-0.70.96-0.98-0.220.84-0.82-0.7-0.78-0.79-0.70.35
-0.85-0.93-0.05-0.650.72-0.81-0.840.36-0.810.8-0.33-0.470.430.460.470.390.46-0.26
-0.48-0.46-0.79-0.720.54-0.68-0.70.36-0.680.680.58-0.790.920.390.460.960.39-0.16
0.970.950.230.9-0.91.00.96-0.81-0.68-0.98-0.220.83-0.8-0.71-0.73-0.76-0.710.44
-0.95-0.92-0.24-0.90.88-0.98-0.980.80.68-0.980.25-0.830.80.70.780.770.7-0.36
-0.080.05-0.35-0.480.33-0.23-0.22-0.330.58-0.220.25-0.670.680.470.530.680.47-0.31
0.740.670.290.97-0.870.830.84-0.47-0.790.83-0.83-0.67-0.97-0.85-0.88-0.92-0.850.53
-0.66-0.6-0.51-0.910.76-0.8-0.820.430.92-0.80.80.68-0.970.710.760.990.71-0.37
-0.74-0.670.23-0.880.83-0.71-0.70.460.39-0.710.70.47-0.850.710.920.61.0-0.72
-0.74-0.660.08-0.90.85-0.74-0.780.470.46-0.730.780.53-0.880.760.920.670.92-0.54
-0.6-0.55-0.63-0.860.69-0.77-0.790.390.96-0.760.770.68-0.920.990.60.670.6-0.29
-0.74-0.670.23-0.880.83-0.71-0.70.460.39-0.710.70.47-0.850.711.00.920.6-0.72
0.510.44-0.290.51-0.670.450.35-0.26-0.160.44-0.36-0.310.53-0.37-0.72-0.54-0.29-0.72
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition

NRX Dividend Paid And Capex Coverage Ratio

Dividend Paid And Capex Coverage Ratio

(3,756.85)

At this time, NRX Pharmaceuticals' Dividend Paid And Capex Coverage Ratio is relatively stable compared to the past year.
Based on the recorded statements, NRX Pharmaceuticals has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Aroon Oscillator Now

   

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
All  Next Launch Module

NRX Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NRX Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NRX Pharmaceuticals' managers, analysts, and investors.
64.3%
Environmental
71.4%
Governance
Social

NRX Fundamentals

Return On Equity-6.83
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200,000%-100,000%0%100,000%200,000%300,000%
Return On Asset-1.46
Current Valuation43.93 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150,000%100,000%150,000%200,000%250,000%300,000%
Shares Outstanding16.92 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%2,500%
Shares Owned By Insiders16.37 %
Shares Owned By Institutions5.94 %
Number Of Shares Shorted1.03 M
Price To Book2.90 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-15,000%-10,000%-5,000%0%5,000%
EBITDA(30.02 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-120,000%-100,000%-80,000%-60,000%-40,000%-20,000%
Net Income(30.15 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%10,000%20,000%30,000%40,000%50,000%60,000%
Cash And Equivalents24.55 M
Cash Per Share0.36 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%0%
Total Debt9.16 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%
Debt To Equity0.02 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-5,000%0%5,000%10,000%15,000%
Current Ratio4.58 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%
Book Value Per Share(1.66) X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-80%-60%-40%-20%0%
Cash Flow From Operations(21.66 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%30,000%
Short Ratio0.38 X
Earnings Per Share(2.11) X
Target Price31.67
Beta1.12
Market Capitalization38.57 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5,000,000,000%10,000,000,000%15,000,000,000%20,000,000,000%25,000,000,000%
Total Asset7.32 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%
Retained Earnings(253.15 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50,000%100,000%150,000%200,000%250,000%
Working Capital(12.16 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset7.32 M

About NRX Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NRX Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRX Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRX Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.